Scientists at the Translational Genomics Research Institute, part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product-targeting antibody, for the treatment of pancreatic cancer.
Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair.
